Product Description
Retatrutide is an investigational once-weekly triple receptor agonist (targeting GIP, GLP-1, and glucagon receptors) developed by Eli Lilly for weight management and type 2 diabetes, not an FDA-approved commercial drug. A 40mg format (such as multi-dose pens or vials) sold online is typically marketed strictly for laboratory research use only or comes from unapproved sources.